Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

ISCHEMIA Questions? Some Answers From David Maron

News Opinion Editor's Corner

ISCHEMIA Questions? Some Answers From David Maron

December 09, 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

Recurrent Events Common Among Young Patients With CAD

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

TCTMD’s Top 10 Most Popular Stories for September 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

October 01, 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

Young Survivors of Childhood Cancer Have Higher, Earlier Risk of CVD Events

News Daily News

Young Survivors of Childhood Cancer Have Higher, Earlier Risk of CVD Events

August 30, 2019

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

August 23, 2019

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.